Non Corticosteroid Anti inflammatory Eyedrops

Non-Corticosteroid Anti-Inflammatory Eyedrops Market Outlook

The global non-corticosteroid anti-inflammatory eyedrops market is projected to reach USD 3.5 billion by 2035, with a compound annual growth rate (CAGR) of approximately 6.2% from 2025 to 2035. The market is witnessing robust growth driven by the increasing prevalence of eye-related disorders, particularly allergic conjunctivitis and dry eye syndrome, which are significantly impacting the quality of life for millions. Additionally, the rising awareness regarding eye care, coupled with a growing geriatric population that is more susceptible to ocular diseases, is further propelling market growth. Advancements in pharmaceutical formulations and an increase in the availability of eye care products through various distribution channels are also contributing to the market's expansion. Moreover, ongoing research and development initiatives aimed at creating more effective and patient-friendly anti-inflammatory eyedrop solutions are expected to bolster market opportunities.

Growth Factor of the Market

The growth of the non-corticosteroid anti-inflammatory eyedrops market is primarily fueled by the escalating incidence of chronic eye conditions and a rising demand for effective treatment options that minimize side effects compared to corticosteroids. Technological advancements in drug delivery systems have also enhanced the efficacy and safety profile of these products, making them more appealing to both healthcare providers and patients. Furthermore, an increasing emphasis on preventive eye care among the aging population is leading to a higher adoption rate of these eyedrops, as they provide relief from inflammation without the adverse effects associated with long-term corticosteroid use. The integration of telemedicine and digital health platforms is streamlining access to treatment, enabling patients to obtain prescriptions and purchase medications more conveniently. Collectively, these factors are creating a fertile landscape for the non-corticosteroid anti-inflammatory eyedrops market.

Key Highlights of the Market

• Increasing prevalence of eye disorders driving demand.
• Technological advancements in drug delivery systems.
• Rising awareness of eye care among the geriatric population.
• Growth in the online pharmacy sector.
• Focus on developing patient-friendly formulations.

By Product Type

NSAIDs Eyedrops:

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) eyedrops are widely used due to their effectiveness in managing inflammation and pain associated with various ocular conditions. These medications, including ketorolac and bromfenac, work by inhibiting cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins responsible for inflammation. The popularity of NSAIDs eyedrops is growing, particularly for post-operative care in cataract surgeries, where inflammation is a common concern. Furthermore, the non-systemic nature of these eyedrops reduces the risk of systemic side effects, making them a preferred choice among healthcare providers. The ease of administration and rapid onset of action are additional benefits that contribute to their increasing adoption in clinical practice.

Antihistamine Eyedrops:

Antihistamine eyedrops are primarily utilized for the treatment of allergic ocular conditions such as allergic conjunctivitis. These eyedrops effectively block histamine receptors, alleviating symptoms like itching, redness, and swelling. With the rising incidence of allergies due to environmental factors, the demand for antihistamine eyedrops is on the rise. Products containing olopatadine have gained significant traction in the market due to their dual-action mechanism that not only inhibits histamine but also stabilizes mast cells, preventing further allergen-induced symptoms. The availability of prescription and over-the-counter formulations has expanded access for patients, making antihistamine eyedrops a vital component of the non-corticosteroid anti-inflammatory eyedrops market.

Immunosuppressive Eyedrops:

Immunosuppressive eyedrops, such as cyclosporine, are used in the management of autoimmune conditions affecting the eyes, particularly uveitis. These medications work by suppressing the immune response that leads to inflammation and tissue damage. Immunosuppressive eyedrops have emerged as critical treatment options for chronic inflammatory conditions where corticosteroids are not suitable for long-term use due to their side effects. The introduction of innovative formulations that enhance the bioavailability and ocular retention of these drugs has also bolstered their market presence. As more healthcare professionals recognize the importance of immunosuppressive therapies in managing ocular inflammation, the demand for these eyedrops is expected to continue to grow.

Others:

Other types of non-corticosteroid anti-inflammatory eyedrops include various formulations that do not fit into the primary categories of NSAIDs, antihistamines, or immunosuppressive agents. These may include newer agents or combination therapies designed to provide dual benefits, enhancing patient compliance and treatment efficacy. The segment is witnessing innovation as companies explore unique formulations that address specific ocular conditions. The flexibility in product development allows for tailored therapies that cater to the diverse needs of patients suffering from different eye ailments. As the market evolves, the introduction of these specialized products is likely to contribute positively to the overall growth of the non-corticosteroid anti-inflammatory eyedrops market.

By Application

Dry Eye:

Dry eye syndrome is an increasingly common ocular condition that significantly impacts patients' quality of life. Non-corticosteroid anti-inflammatory eyedrops are pivotal in managing this condition, as they help alleviate inflammation and discomfort associated with dry eyes. The growing prevalence of dry eye syndrome, particularly among the aging population and due to lifestyle factors such as prolonged screen time, has led to a heightened demand for effective treatment options. Products that combine anti-inflammatory agents with lubricating properties are gaining popularity, providing multifaceted relief to patients. This segment is expected to witness substantial growth as awareness regarding dry eye syndrome and its treatment options continues to expand.

Allergic Conjunctivitis:

Allergic conjunctivitis is characterized by inflammation of the conjunctiva due to allergen exposure, leading to symptoms such as redness, itching, and tearing. Non-corticosteroid anti-inflammatory eyedrops, especially antihistamines, play a significant role in managing this condition. The increasing prevalence of environmental allergies is driving the demand for effective treatments, and patients are seeking solutions that provide rapid relief without the side effects of corticosteroids. With the growing availability of these eyedrops in both prescription and OTC forms, the segment is poised for growth as more individuals seek out effective management strategies for allergic conjunctivitis. Continuous advancements in formulation technologies are also enhancing the efficacy and stability of these products.

Uveitis:

Uveitis is a serious inflammatory condition affecting the uveal tract of the eye, necessitating prompt and effective treatment to prevent vision loss. Non-corticosteroid anti-inflammatory eyedrops, particularly immunosuppressive agents, are critical in controlling inflammation in uveitis cases. The rising incidence of autoimmune diseases and the recognition of the importance of early intervention are driving the demand for these eyedrops. Healthcare professionals are increasingly opting for non-corticosteroid options to minimize the risk of complications associated with long-term corticosteroid use. As awareness of the severity of uveitis grows, the market for anti-inflammatory eyedrops specifically targeting this condition is expected to expand, presenting opportunities for pharmaceutical companies.

Others:

The 'Others' application segment encompasses various other conditions where non-corticosteroid anti-inflammatory eyedrops may be utilized. This includes less common ocular inflammatory disorders or post-operative care for surgeries beyond cataracts. As research continues to highlight the efficacy of these eyedrops in diverse applications, this segment presents potential for growth. The increasing understanding of ocular inflammation and the growing body of clinical evidence supporting the use of non-corticosteroid options are likely to drive demand in this area. Furthermore, the emergence of new therapeutic indications for existing products can also contribute to the expansion of this segment.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of non-corticosteroid anti-inflammatory eyedrops, particularly for patients requiring specialized care. These pharmacies are often the first point of contact for patients undergoing eye surgeries or those with severe ocular conditions. The presence of trained healthcare professionals in hospital settings facilitates the accurate dispensing of medications and provides essential patient education regarding usage and potential side effects. Furthermore, hospital pharmacies often have access to a broader range of products, including those that may not be available in retail or online pharmacies. As the number of eye surgeries increases, the demand for hospital pharmacy distribution of these eyedrops is anticipated to rise, reflecting the importance of this channel in the overall market landscape.

Retail Pharmacies:

Retail pharmacies are pivotal in making non-corticosteroid anti-inflammatory eyedrops accessible to the general public. With a growing number of individuals seeking over-the-counter solutions for their eye-related issues, retail pharmacies have become a primary distribution channel for these products. The convenience of retail pharmacies allows patients to easily obtain medications without the need for hospital visits, supporting better adherence to treatment regimens. Additionally, the expansion of retail pharmacy chains and the introduction of personalized services such as consultations with pharmacists have enhanced the shopping experience for patients seeking eye care solutions. As consumer behavior shifts towards convenience and accessibility, the retail pharmacy segment is expected to see significant growth in the coming years.

Online Pharmacies:

The rise of online pharmacies has transformed the landscape of healthcare distribution, including non-corticosteroid anti-inflammatory eyedrops. Patients increasingly prefer the convenience of purchasing medications from the comfort of their homes, particularly for chronic conditions that require ongoing treatment. Online pharmacies offer a wide range of products, often with competitive pricing and home delivery options. This channel has become particularly relevant in the post-COVID-19 era, where many patients are seeking to minimize in-person visits. The growth of telemedicine and digital health initiatives has also facilitated easier access to prescriptions for these eyedrops, leading to an expected surge in online pharmacy sales. As e-commerce continues to expand, the online pharmacy segment is anticipated to play a crucial role in the distribution of non-corticosteroid anti-inflammatory eyedrops.

By Ingredient Type

Ketorolac:

Ketorolac is a widely used NSAID eyedrop known for its potent anti-inflammatory properties, making it a common choice for managing postoperative pain and inflammation after cataract surgery. Its effectiveness in reducing inflammation has made it a staple in ophthalmology, ensuring its continued prominence in the market. Ketorolac's formulation allows for easy absorption in the ocular tissues, providing rapid relief to patients. The growing number of cataract surgeries and the increasing focus on minimizing postoperative discomfort are driving demand for ketorolac-based eyedrops. As more healthcare providers recognize the benefits of using ketorolac for ocular inflammation, this ingredient is likely to see sustained growth within the non-corticosteroid anti-inflammatory eyedrops market.

Olopatadine:

Olopatadine is predominantly used in antihistamine eyedrops for treating allergic conjunctivitis. Its efficacy in blocking histamine receptors and stabilizing mast cells makes it highly effective in alleviating symptoms associated with allergic reactions. The demand for olopatadine is witnessing significant growth due to the increasing prevalence of allergic conditions resulting from environmental factors. With its dual-action capabilities, olopatadine offers a comprehensive solution for patients seeking relief from allergic eye symptoms. The development of various formulations, including once-daily dosages, has further enhanced patient adherence and satisfaction. As awareness regarding allergy management continues to grow, olopatadine's presence in the market is expected to expand considerably.

Cylosporine:

Cylosporine is an invaluable immunosuppressive agent used in the management of uveitis and dry eye syndrome. By modulating the immune response, cyclosporine helps reduce inflammation and promote tear production, addressing the underlying causes of dry eye syndrome. The growing awareness of chronic inflammatory conditions of the eye and the need for long-term treatment options are driving the demand for cyclosporine-based eyedrops. This ingredient has gained a reputation for providing effective control of ocular inflammation while minimizing the potential side effects associated with corticosteroids. As more patients seek alternative therapies, cyclosporine is likely to witness a rise in adoption, further solidifying its role in the non-corticosteroid anti-inflammatory eyedrops market.

Bromfenac:

Bromfenac is another prominent NSAID ingredient in the non-corticosteroid anti-inflammatory eyedrops category. It is particularly valued for its efficacy in managing postoperative inflammation and pain following cataract surgery. Bromfenac's unique formulation enhances its penetration into ocular tissues, ensuring rapid action and prolonged therapeutic effects. The ongoing rise in cataract surgeries and the demand for effective anti-inflammatory medications are driving the growth of bromfenac-based eyedrops. Additionally, the development of sustained-release formulations is expected to improve patient compliance and overall treatment outcomes, further contributing to the ingredient's market growth.

Diclofenac:

Diclofenac is a well-established NSAID utilized in the treatment of ocular inflammation, particularly in postoperative scenarios. Its potent anti-inflammatory properties make it an effective choice for reducing pain and swelling after eye surgeries. Diclofenac eyedrops have been widely adopted due to their favorable safety profile and ease of administration. The continuous rise in surgical procedures and patients' preference for non-corticosteroid options are driving the demand for diclofenac-based products in the market. As healthcare providers increasingly seek effective alternatives to corticosteroids for inflammation management, diclofenac is expected to maintain its presence as a key ingredient in the non-corticosteroid anti-inflammatory eyedrops market.

By Region

The regional analysis of the non-corticosteroid anti-inflammatory eyedrops market reveals varying dynamics, driven by factors such as healthcare infrastructure, population demographics, and the prevalence of eye disorders. North America holds a significant market share, accounting for approximately 40% of the global market in 2025, largely due to advanced healthcare systems, a high prevalence of eye diseases, and increased spending on health. The United States, with its vast population and a strong emphasis on healthcare innovation, is the leading contributor to this growth. The region is characterized by a robust pharmaceutical sector, ensuring the availability of a diverse range of non-corticosteroid anti-inflammatory eyedrops, which is expected to grow at a CAGR of 5.8% over the forecast period. As more patients seek effective treatments for ocular conditions, North America is poised to remain a dominant player in this market.

Europe is another vital region in the non-corticosteroid anti-inflammatory eyedrops market, expected to account for approximately 30% of the market share by 2035. The region benefits from a high awareness of eye care and a growing geriatric population, which is increasingly at risk for eye-related disorders. Countries such as Germany, France, and the UK are witnessing significant growth due to their advanced healthcare systems and focus on innovative treatment options. The European market is anticipated to expand at a CAGR of 6.5%, driven by the rising prevalence of allergies and chronic inflammatory conditions. As healthcare providers continue to emphasize patient-centered care and effective management strategies for eye disorders, Europe’s contribution to the non-corticosteroid anti-inflammatory eyedrops market is expected to strengthen further.

Opportunities

One of the key opportunities in the non-corticosteroid anti-inflammatory eyedrops market lies in the development of innovative formulations that enhance bioavailability and patient compliance. As research and development efforts continue to focus on improving drug delivery systems and creating user-friendly packaging, there is potential for more effective and accessible treatments. Furthermore, the growing trend towards personalized medicine offers significant opportunities for tailored therapies catering to individual patient needs. By harnessing advancements in biotechnology and pharmacogenomics, manufacturers can create specialized formulations that target specific demographics or conditions, fostering targeted therapeutic interventions. This evolution in product development is likely to attract new players into the market, driving competition and innovation.

Additionally, expanding distribution channels, particularly through online pharmacies, presents a lucrative opportunity for market growth. The shift in consumer behavior towards e-commerce has accelerated the demand for convenient access to medications, including non-corticosteroid anti-inflammatory eyedrops. Leveraging digital platforms to promote products and engage with customers can significantly enhance brand visibility and market penetration. Strategic partnerships with telemedicine providers can also streamline prescription processes and improve patient access to these vital treatments. As more individuals seek convenient healthcare solutions, the market's growth potential through online sales channels is substantial, likely leading to increased revenue for established and emerging companies in the sector.

Threats

Despite the promising growth trajectory of the non-corticosteroid anti-inflammatory eyedrops market, several threats could impede progress. The emergence of generic competition poses a significant challenge, as the expiration of patents for key products can lead to a surge in lower-cost alternatives. This situation could impact the revenue and market share of established brands, as patients and healthcare providers may gravitate towards more affordable options without considering efficacy or safety. Additionally, the potential for product recalls or safety concerns surrounding specific formulations can erode consumer trust and affect overall market stability. Regulatory challenges may also arise, particularly as the industry navigates stringent approval processes for new products, further complicating market dynamics.

Another substantial threat to the market is the rising awareness of alternative therapies and holistic approaches to managing eye conditions. Patients are increasingly exploring options such as dietary supplements, lifestyle changes, and natural remedies as alternatives to traditional medications. This shift in consumer preference could reduce the demand for non-corticosteroid anti-inflammatory eyedrops, particularly if these alternatives are perceived as safer or more effective. Healthcare professionals may also be swayed by emerging evidence supporting non-pharmaceutical interventions, which could lead to decreased prescriptions for eyedrops. As the market continues to evolve, addressing these threats will be essential for maintaining a competitive edge in the non-corticosteroid anti-inflammatory eyedrops market.

Competitor Outlook

• Allergan, Inc.
• Alcon, Inc.
• Eyevance Pharmaceuticals, LLC
• Novartis AG
• Shire PLC
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co., Ltd.
• Hikma Pharmaceuticals PLC
• Akorn, Inc.
• Ocular Therapeutix, Inc.
• Imprimis Pharmaceuticals, Inc.
• InSite Vision Incorporated
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.

The competitive landscape of the non-corticosteroid anti-inflammatory eyedrops market is characterized by a mix of established pharmaceutical giants and innovative emerging companies. Major players such as Allergan and Novartis dominate the market, leveraging their extensive experience, robust R&D capabilities, and wide distribution networks to drive their product offerings. These companies continuously invest in research and development to innovate and expand their portfolios, ensuring they meet the evolving needs of consumers and healthcare providers alike. Additionally, strategic mergers and acquisitions are common as larger firms seek to enhance their market position and diversify their product ranges. This competitive intensity fosters an environment of continuous improvement and innovation, ultimately benefiting patients.

Among the key competitors, Alcon stands out for its strong focus on eye care products, including a comprehensive range of non-corticosteroid anti-inflammatory eyedrops. The company has established a robust global presence and is recognized for its commitment to advancing ocular health through research and innovative therapies. Bausch Health, another significant player, has a diverse portfolio that includes various ophthalmic solutions, positioning it well within the non-corticosteroid anti-inflammatory segment. The company is actively working on expanding its product offerings and enhancing its market share through targeted marketing and strategic distribution partnerships.

Santen Pharmaceutical Co., Ltd. is also gaining traction in the non-corticosteroid anti-inflammatory eyedrops market by focusing on specialized therapies for ocular diseases. The company emphasizes innovation and the development of unique formulations that cater to unmet patient needs, thereby enhancing its competitive edge. Additionally, the rise of smaller firms and biotech companies, such as Ocular Therapeutix, highlights the growing interest in niche markets within the ocular healthcare space. These companies often focus on developing novel delivery systems and groundbreaking formulations, setting themselves apart from traditional competitors and contributing to a dynamic and competitive market landscape.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Shire PLC
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Akorn, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Alcon, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Allergan, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Ocular Therapeutix, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Hikma Pharmaceuticals PLC
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 InSite Vision Incorporated
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bausch Health Companies Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Eyevance Pharmaceuticals, LLC
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Imprimis Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Santen Pharmaceutical Co., Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Non Corticosteroid Anti inflammatory Eyedrops Market, By Application
    • 6.1.1 Dry Eye
    • 6.1.2 Allergic Conjunctivitis
    • 6.1.3 Uveitis
    • 6.1.4 Others
  • 6.2 Non Corticosteroid Anti inflammatory Eyedrops Market, By Ingredient Type
    • 6.2.1 Ketorolac
    • 6.2.2 Olopatadine
    • 6.2.3 Cyclosporine
    • 6.2.4 Bromfenac
    • 6.2.5 Diclofenac
  • 6.3 Non Corticosteroid Anti inflammatory Eyedrops Market, By Distribution Channel
    • 6.3.1 Hospital Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Non Corticosteroid Anti inflammatory Eyedrops Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Non Corticosteroid Anti inflammatory Eyedrops market is categorized based on

By Application

• Dry Eye
• Allergic Conjunctivitis
• Uveitis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Ketorolac
• Olopatadine
• Cyclosporine
• Bromfenac
• Diclofenac

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Allergan, Inc.
• Alcon, Inc.
• Eyevance Pharmaceuticals, LLC
• Novartis AG
• Shire PLC
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co., Ltd.
• Hikma Pharmaceuticals PLC
• Akorn, Inc.
• Ocular Therapeutix, Inc.
• Imprimis Pharmaceuticals, Inc.
• InSite Vision Incorporated
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.